Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
16 Octubre 2024 - 6:00AM
Business Wire
Both programmes demonstrate Exscientia’s
ability to design highly differentiated, potentially best-in-class
molecules
Exscientia will receive $15 million for
achieving these milestones and is eligible for over $600 million in
additional milestone payments for these two programmes as well as
high-single-digit to mid-teen royalties
Three programmes in the partnership have now
advanced through initial milestones with multiple more progressing
at earlier stages
Exscientia plc (Nasdaq: EXAI) today announced the advancement of
two additional discovery programmes within its collaboration with
Sanofi, with Exscientia receiving an aggregate of $15 million in
milestone payments. Both lead compounds have met the product
profile requirements, set by both Exscientia and Sanofi, to enable
a transition to the lead optimisation phase within the
collaboration. Both programmes have also shown a high level of
differentiation in early profiling and have the potential to
produce best-in-class assets.
“We are excited to announce the advancement of these programmes.
This is testament to our consistent ability to design compounds
that solve complex problems,” said David Hallett, Ph.D., interim
Chief Executive Officer and Chief Scientific Officer of Exscientia.
“We look forward to continuing to work with Sanofi to advance these
programmes towards development, and ultimately working together to
bring potential new treatment options to patients with significant
unmet need.”
Exscientia will receive $15 million, in aggregate, for achieving
these milestones. The payment is expected to be received by
Exscientia in the fourth quarter of 2024 and reflected as cash
inflows from collaborations and recognised as revenue over the
duration of the collaboration. For these two programmes, Exscientia
is also eligible to receive additional pre-commercial milestone
payments of over $300 million and commercial milestones of over
$300 million as well as tiered royalties on product sales ranging
from high-single-digits to mid-teens, subject upon the achievement
of certain specified research, development, regulatory and
commercial milestones.
About Exscientia Exscientia is a technology-driven drug
design and development company, committed to creating more
effective medicines for patients, faster. Exscientia combines
precision design with integrated experimentation, aiming to invent
and develop the best possible drugs in the most efficient manner.
Operating at the interfaces of human ingenuity, artificial
intelligence (AI), automation and physical engineering, we
pioneered the use of AI in drug discovery as the first company to
progress AI-designed small molecules into a clinical setting. We
have developed an internal pipeline focused on oncology, while our
partnered pipeline extends to many other therapeutic areas. By
leading this new approach to drug creation, we believe we can
change the underlying economics of drug discovery and rapidly
advance the best scientific ideas into medicines for patients.
For more information visit us on www.exscientia.com or follow us
on LinkedIn @ex-scientia and X @exscientiaAI.
Forward-looking Statements This press release contains
certain forward-looking statements within the meaning of the “safe
harbor” provisions of the Private Securities Litigation Reform Act
of 1995. Words such as “anticipates,” “believes,” “expects,”
“intends,” and “projects” or similar expressions are intended to
identify forward-looking statements. All statements, other than
statements of historical facts, included in this press release are
forward-looking statements. These statements include, but are not
limited to, statements regarding the further development of the two
programmes under the collaboration with Sanofi, including advancing
the product candidates through optimisation phrase and into the
clinic; the creation of best-in-class therapies which meet unmet
medical needs in inflammation and oncology; expectations and
benefits related to the Sanofi collaboration including the
development of additional molecule programmes and potential for
future milestone payments; and the ability of Exscientia’s
technology to design compounds to create more effective medicines
for patients. Such statements are subject to a number of risks,
uncertainties and assumptions, including those related to: the
initiation, scope and progress of Exscientia’s and its partners’
planned and ongoing preclinical studies and clinical trials and
ramifications for the cost thereof; clinical, scientific,
regulatory and technical developments; the development and
deployment of new technology and facilities; the process of
discovering, developing and commercialising product candidates that
are safe and effective for use as human therapeutics and the
endeavour of building a business around such product candidates;
and the process of creating a combined company with Recursion
Pharmaceuticals and subsequent activities by any such combined
company. In light of these risks and uncertainties, and other risks
and uncertainties that are described in the Risk Factors section
and other sections of Exscientia’s Annual Report on Form 20-F,
filed with the Securities and Exchange Commission (SEC) on March
21, 2024, and other filings that Exscientia makes with the SEC from
time to time (which are available at https://www.sec.gov/), the
events and circumstances discussed in such forward-looking
statements may not occur, and Exscientia’s actual results could
differ materially and adversely from those anticipated or implied
thereby. Although Exscientia’s forward-looking statements reflect
the good faith judgement of its management, these statements are
based only on facts and factors currently known by the Company. As
a result, investors are cautioned not to rely on these
forward-looking statements. Exscientia undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise, except
as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241016255653/en/
Investor Relations: Sara Sherman
investors@exscientia.ai
Media: David Keown media@exscientia.ai
Exscientia (NASDAQ:EXAI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Exscientia (NASDAQ:EXAI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024